Press "Enter" to skip to content

BeiGene cancer drug fails in study against AbbVie: J&J’s Imbruvica

BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa’s approval to treat patients with mantle cell lymphoma, who have received at least one prior therapy.

Original source: